TCTR20230410004已完成4 期
The Plasma Level of Branded Generic Apixaban in Patients with Atrial Fibrillation
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •Adults aged > 20 years with clinical AF who are eligible for DOAC according to latest clinical practice guidelines.
排除标准
- •(1) Received another DOAC before this study
- •(2) Moderate and severe mitral valve stenosis
- •(3) Underwent mechanical valve replacement
- •(4) Estimated glomerular filtration rate (eGFR) by Cockcroft-Gault formula less than 15 ml/min/1.73m2, or CKD stage V / end-stage kidney disease (ESKD)
- •(5) Chronic liver disease with Child-Turcotte-Pugh score 7 points or higher
- •(6) Pregnancy or breastfeeding
- •(7) Poor adherence to medications
- •(8) Inability to perform proper self-care
- •(9) Inability to provide an informed consent
研究者
相似试验
已完成
不适用
Bioequivalence of ApixabaIRCT20210201050197N4Shahid Beheshti University of Medical Sciences24
招募中
不适用
The efficacy and safety of low dose apixaban in patients with non-valvular atrial fibrellation in real world practive: a prospective, multicenter , non-interventional studyDiseases of the circulatory systemKCT0005916Keimyung University Dongsan Hospital1,673
招募中
Unknown
Investigating the in vivo bioequivalence of Apixaban tabletIn the present study, the products will be administered to healthy volunteers..IRCT20220211053992N10Tabriz University of Medical Sciences24
已完成
不适用
Comparative in vivo evaluation of 2 ?Apixaban 5 mg Tablet formulations.IRCT20180620040164N37Actover Pharmaceutical Co.24
尚未招募
不适用
Comparative bioequivalence study of the Apixaban 5-mg Tablets manufactured by Darman Yab Darou Company-.IRCT20130313012810N10Darman Yab Darou Pharmaceutical Company24